Sugi Predict

Sugi Predict / Compounds / SCHEMBL190024

SCHEMBL190024

SCHEMBL190024

CC1CN(C(=O)O)CCN1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BIRC2 Q13490 1/20 0.47
▸ HRH4 Q9H3N8 1/20 0.44
▸ REN P00797 2/20 0.39
▸ CHRNB2 P17787 1/20 0.38
▸ CHRNA3 P32297 1/20 0.38
▸ CHRNA4 P43681 1/20 0.38
▸ CHRNB3 Q05901 1/20 0.38
▸ CHRNA6 Q15825 1/20 0.38
▸ TP53 P04637 1/20 0.37
▸ MDM2 Q00987 1/20 0.37
▸ CA2 P00918 2/20 0.35
▸ CA12 O43570 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ PLD1 Q13393 2/20 0.34
▸ PLD2 O14939 1/20 0.34
▸ CNR1 P21554 1/20 0.34
▸ CHKA P35790 1/20 0.34
▸ SIGMAR1 Q99720 1/20 0.33
▸ PAK4 O96013 3/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL190023 1.00 BIRC2 (0.47) BIRC2HRH4RENCHRNB2CHRNA3
SCHEMBL1181669 1.00 BIRC2 (0.47) BIRC2HRH4RENCHRNB2CHRNA3
SCHEMBL4033981 0.88 BIRC2 (0.49) BIRC2HRH4RENCHRNB2CHRNA3
SCHEMBL25224263 0.88 BIRC2 (0.49) BIRC2HRH4RENCHRNB2CHRNA3
SCHEMBL28621816 0.86 BIRC2 (0.51) BIRC2HRH4RENCHRNB2CHRNA3
SCHEMBL27957087 0.84 BIRC2 (0.49) BIRC2HRH4RENCHRNB2CHRNA3
SCHEMBL28120270 0.84 BIRC2 (0.49) BIRC2HRH4RENCHRNB2CHRNA3
SCHEMBL28048803 0.84 BIRC2 (0.49) BIRC2HRH4RENCHRNB2CHRNA3
SCHEMBL2422071 0.83 BIRC2 (0.47) BIRC2HRH4RENCHRNB2CHRNA3
SCHEMBL2418463 0.83 BIRC2 (0.47) BIRC2HRH4RENCHRNB2CHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 741 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3250209-B1 COMT INHIBITING METHODS AND COMPOSITIONS LIEBER INST FOR BRAIN DEVELOPMENT (US) 2023-09-13 — — EP claimed
WO-2023150653-A1 PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS GENENTECH, INC. (US) 2023-08-10 — — WO claimed
US-20230250074-A1 PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS GENENTECH, INC. (US) 2023-08-10 — — US claimed
CN-115466259-A Preparation method of KRAS G12C inhibitor sotoxib 山东大学 2022-12-13 — — CN claimed
EP-4720068-A1 COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE Beone Medicines I GmbH (CH) 2026-04-08 — — EP disclosed
US-20260077051-A1 COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE BEONE MEDICINES I GMBH (CH) 2026-03-19 — — US disclosed
EP-4665331-A1 ALPHA-SYNUCLEIN BINDERS AND METHODS OF USE Merck Sharp & Dohme LLC (US) 2025-12-24 — — EP disclosed
US-20250381187-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME AMGEN INC. (US) 2025-12-18 — — US disclosed
US-20250332266-A1 COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE BEIGENE SWITZERLAND GMBH (CH) 2025-10-30 — — US disclosed
US-12440491-B2 KRAS G12C inhibitors and methods of using the same AMGEN INC. (US) 2025-10-14 — — US disclosed
EP-4615850-A1 COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE BeiGene Switzerland GmbH (CH) 2025-09-17 — — EP disclosed
US-20250276981-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. 2025-09-04 — — US disclosed
EP-1226159-A1 SUBSTITUTED DIPEPTIDES HAVING NOS INHIBITING ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-31 — — EP disclosed
EP-1171432-A1 ADAMANTANE DERIVATIVES AstraZeneca AB (SE) 2002-01-16 — — EP disclosed
EP-1105135-A4 ANTIVIRAL INDOLEOXOACETYL PIPERAZINE DERIVATIVES BRISTOL MYERS SQUIBB CO (US) 2001-12-12 — — EP disclosed
WO-2001046200-A1 NOVEL PIPERIDINE AND PIPERAZINE DERIVATIVES ASTRAZENECA AB (SE) 2001-06-28 — — WO disclosed
EP-1105135-A1 ANTIVIRAL INDOLEOXOACETYL PIPERAZINE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2001-06-13 — — EP disclosed
WO-2001032690-A1 SUBSTITUTED DIPEPTIDES HAVING NOS INHIBITING ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-05-10 — — WO disclosed
WO-2000076521-A1 ANTIVIRAL INDOLEOXOACETYL PIPERAZINE DERIVATIVES BRISTOL-MYERS SQUIBB COMPANY (US) 2000-12-21 — — WO disclosed
WO-2000061569-A1 ADAMANTANE DERIVATIVES ASTRAZENECA AB (SE) 2000-10-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250276981-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS BCL6, BCL6B, BCOR BIRC2 44/4885HRH4 3870/4885REN 1977/4885
US-20260077051-A1 COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE EGFR, ERBB3, ERBB2 BIRC2 1854/4885HRH4 1385/4885REN 1555/4885
US-20250381187-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME KRAS, NRAS, HRAS BIRC2 185/4885HRH4 2747/4885REN 605/4885
US-20250332266-A1 COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE EGFR, ERBB2, ERBB3 BIRC2 566/4885HRH4 3359/4885REN 3480/4885
US-20230250074-A1 PROCESS FOR SYNTHESIS OF QUINAZOLINE COMPOUNDS HCCS, NQO2, SQLE BIRC2 2107/4885HRH4 1329/4885REN 2727/4885
US-12440491-B2 KRAS G12C inhibitors and methods of using the same KRAS, NRAS, HRAS BIRC2 185/4885HRH4 2747/4885REN 605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.